TruScreen Launches 260,000 Women Screening Program in HCMC

NZX/ASX Announcement

22 April 2025

TruScreen launches 260,000 women screening program, at
Ho Chi Minh City over 5 years
• A 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam
was launched on 12 April, 2025
• The program will use TruScreen’s unique AI-enabled, real time, non-invasive, cervical
cancer screening device as its primary screening methodology.
• Titled ‘Community-based Cervical Cancer Screening Program’ the program will be
conducted by a partnership between TruScreen Group Ltd (TruScreen), Ho Chi Minh City
Public Health Association (HPHA) and distributor Gorton Health Services (GHS)
• The program structure was developed following the previously announced signing of an
MOU by the three parties in November 2024.
• TruScreen was selected as the primary screening methodology for the capability of its
unique, AI-enabled real time cervical cancer screening technology to assist the Government
of Vietnam achieve its goal of screening 60% of women aged 30 to 54 for cervical cancer
(currently only 25%). The addressable screening population of women in Vietnam aged 18
to 65 is 36 million.


Truscreen Group Limited (NZX/ASX:TRU) (Truscreen or the Company) is pleased to announce the
launching of a 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam
on 12April, 2025 using TruScreen’s unique AI-enabled, real time, non-invasive, cervical cancer screening
device.
The program is a partnership between TruScreen, Ho Chi Minh City Public Health Association (HPHA) and
distributor Gorton Health Services (GHS). A tripartite Memorandum of Understanding (MOU) was signed
in November 2024.
The formal Agreement for the program was signed on 12 April 2025 in Ho Chi Minh City by Dr Le Truang
Jiang (President of HPHA), Mr Tran An Bao (CEO GHS Vietnam) and Mr Tony Ho (Chair, TruScreen).

Mr Tony Ho, Chair TruScreen, Dr Le Truong Jiang, President HPHA and Mr Tran An Bao, CEO GHS
The keynote speech inaugurating the program was delivered by Prof. Dr. Nguyen Chan Hung, President of
Vietnam Cancer Association to an audience including representatives of the Ho Chi Minh City Public
Health Association, the Ho Chi Minh City Centre for Disease Control, The Vietnam Cancer Association,
The Ho Chi Minh City Health Centres Reproductive Health Department and the Australian Consulate in
Ho Chi Minh City.

Representatives of the District Health Centres, the Australian Trade Commission, the HCMC CDC,
HCMC HPHA, Vietnam Cancer Assoc, GHS and TruScreen

The Government of Vietnam has implemented the National Action Plan on Cervical Cancer Prevention
(2016-2025), with the goal of screening 60% of women aged 30 to 54 for cervical cancer. Currently, about
25% of Vietnamese women have ever been screened for this condition. The primary challenge is that
many women are unaware of the risk of cervical cancer and the benefits and importance of early
screening for cervical cancer detection.

The objectives of the Community-based Cervical Cancer Screening Program are:
• Promote awareness, attitudes, and preventive practices for cervical cancer among women
• Collect large-scale epidemiological data on cervical cancer and pre-cancer in Vietnam
• Develop a proactive, community-based cervical cancer screening model for future nationwide
implementation
• Contribute to the citywide elimination of cervical cancer in line with WHO guidelines and
Vietnam Ministry of Health

TruScreen will be the screening methodology of choice for the program. TruScreen was selected for
its unique, AI-enabled, real time, non-invasive cervical cancer screening technology, requiring no
cytology or other laboratory infrastructure. TruScreen’s portability, ease of use and accurate AI enabled
algorithm delivering real time results align with the programs objective for early detection in large
populations.
Ho Chi Minh City Public Health Association (HPHA) will organize and manage the overall project’s
implementation, including promotion of the program, recruitment of social workers, securing local
government approvals and agreements with community health centres and hospitals. HPHA is a socio-
professional organization established in 2007 by the Peoples Committee of Ho Chi Minh City and is
charged with communication and education on community health management as well as implementing
programs, projects and community health events in Ho Chi Minh City.
Gorton Health Services Company Limited (GHS), the authorized distributor of TruScreen in
Vietnam, will coordinate between TruScreen and HPHA, as well as import, distribute and install the
TruScreen products (device and SUS) to screening locations, provide training and support, and collect,
compile, and report screening data for analysis.

Program delivery
• Social workers will be trained on the details of cervical cancer screening and visit their local
community door-to-door to educate women on cervical cancer risk and register participants for
the program. The preferential target population for screening will be women 30 to 49 who have
had sexual intercourse and present as high risk due to multiple children, HPV infection, living with
HIV, smoking (etc)
• Screening will take place at the gynaecology clinics of the District Health Centres and high-tech
private clinics. Three major hospitals will provide technical support: Tu Du Hospital, Hung Vuong
Hospital, and Ung Buou Hospital.
• Media support will be provided by the Ho Chi Minh City Women's Union.
• The program will begin in Ho Chi Minh City, with plans for gradual expansion to other provinces
across Vietnam.

TruScreen CEO, Marty Dillon commented: "This program with its target of Screening 260,000 women
may save the lives of over 2,600
mothers, daughters, sisters, wives and friends. TruScreen was identified
as the ideal screening technology for its unique ability to provide accurate, real time results without the
need for any expensive laboratory infrastructure and its portability which allows for the program to ‘go to
the community’, increasing screening uptake amongst the women of Ho Chi Minh City."
“This HPHA screening program will also serve as an important reference site for neighbouring countries
who may be considering similar large scale screening program to improve Women’s Health.”

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:
Martin Dillon
Chief Executive Officer
martindillon@truscreen.com
Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer
screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines,
among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing
facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National
Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the
Russian guidelines for the screening of cervical cancer.
In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To
date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and
Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a
special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the
cells. Then it is sent to a laboratory for a pathologist to examine under a
microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-
procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix,
onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can
be done at the same time, such as the human papillomavirus (HPV)
test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same
sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked
to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test
may also be done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence
or absence of a condition. If individuals who have the condition are considered "positive" and those who
don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives
and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on the
individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and
Australia, please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)
Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council